Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

02 October 2008

Safety and tolerability of 600 mg clopidogrel bolus in patients with acute ischemic stroke: preliminary experience

M. Fared K. SuriADEF, Haitham M. HusseinBCE, Mohamed M. AbdelmoulaBC, Afshin A. DivaniEG, Adnan I QureshiADEF

Med Sci Monit 2008; 14(10): PI39-44 :: ID: 869394

Abstract

Background
There is a high risk of recurrence within the first 72 hours of ischemic stroke. Without bolus, the peak effect of clopidogrel may be delayed for 72 hours. A bolus may shorten this time but its safety in acute ischemic stroke is unknown.
Material and Method
All patients with acute ischemic stroke or transient ischemic attack within a 10 month period were administered 600 mg clopidogrel bolus if they were already taking aspirin regularly, or had aspirin allergy or intolerance. Demographic data, duration to initiation of therapy, National Institute of Health Stroke Scale score (NIHSSS) at baseline and at 24 hours were collected. Brain imaging studies were reviewed for hemorrhagic transformation. Wilcoxin rank sum test was used for comparison of NIHSSS over time.
Results
A total of 20 patients (mean age 66+/-14, men n=8) were loaded with clopidogrel because of aspirin failure (n=16), aspirin allergy (n=1), aspirin intolerance secondary to gastritis (n=2) or stent placement in the setting of acute stroke (n=1). Median time interval between clopidogrel bolus and symptom onset was 25 hours. The median NIHSSS at 24 hours (1, range 0-15) was significantly (p<0.01) lower than the NIHSSS at baseline (3, range 0-24). Neurological deterioration (NIHSSS increase > or =4 points) or hemorrhagic transformation was not seen in any patient.
Conclusions
A 600 mg clopidogrel bolus prior to initiating regular dose clopidogrel in the setting of acute ischemic stroke was safe. The potential for risk reduction in early recurrent stroke needs to be studied in future studies.

Keywords: Stroke - prevention & control, Recurrence, Prospective Studies, Platelet Aggregation Inhibitors - therapeutic use, Brain Ischemia - prevention & control, Aspirin - therapeutic use, Ticlopidine - therapeutic use, Aged, 80 and over

Add Comment 0 Comments

Editorial

01 April 2024 : Editorial  

Editorial: Forty Years of Waiting for Prevention and Cure of HIV Infection – Ongoing Challenges and Hopes for Vaccine Development and Overcoming Antiretroviral Drug Resistance

Dinah V. Parums

DOI: 10.12659/MSM.944600

Med Sci Monit 2024; 30:e944600

0:00

In Press

04 Mar 2024 : Clinical Research  

Injury-Admission Time is an Independent Risk Factor for Deep Vein Thrombosis in Older Patients with Osteopo...

Med Sci Monit In Press; DOI: 10.12659/MSM.943587  

0:00

04 Mar 2024 : Clinical Research  

Evaluation of the Interrater Reliability of Sonographic Measurements of Muscle Thickness of 38 Piriformis M...

Med Sci Monit In Press; DOI: 10.12659/MSM.943720  

0:00

05 Apr 2024 : Clinical Research  

Comparative Analysis of Transoral Endoscopic Parathyroidectomy Vestibular Approach and Focused Open Surgery...

Med Sci Monit In Press; DOI: 10.12659/MSM.944128  

05 Mar 2024 : Clinical Research  

Muscular Function Recovery from General Anesthesia in 132 Patients Undergoing Surgery with Acceleromyograph...

Med Sci Monit In Press; DOI: 10.12659/MSM.942780  

Most Viewed Current Articles

17 Jan 2024 : Review article  

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

14 Dec 2022 : Clinical Research  

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990

0:00

16 May 2023 : Clinical Research  

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

01 Jan 2022 : Editorial  

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750